Aura Biosciences, Inc. (AURA)

11.21 +1.08 (+10.66%) At close: 04:00PM EST

Aura Biosciences, Inc.

85 Bolton Street
Cambridge, MA 02140
United States
617 500 8864
https://www.aurabiosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 52

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Elisabet de los Pinos Ph.D.	Founder, CEO, Pres & Director	676.62k	N/A	1974
Ms. Julie B. Feder	CFO, Sec. & Treasurer	505.45k	N/A	1970
Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBA	Chief Medical Officer and Head of R&D	564.22k	N/A	1965
Dr. Mark A. De Rosch Ph.D.	Chief Operating Officer	N/A	N/A	1964
Mr. Paulo Carvalho	VP of Technical Operations	N/A	N/A	N/A
Mr. Joseph Lyons	VP of HR	N/A	N/A	N/A
Ms. Michele Keough M.B.A.	Sr. VP of Project Management and Device Supply Chain	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Aura Biosciences, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 8. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.